These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 32681460

  • 1. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J, Bonnet F, Wu J, Bonnemaire M, Gupta S, Cambron-Mellott JM, Nicholls C, Müller-Wieland D.
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [Abstract] [Full Text] [Related]

  • 2. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A, Brown RE, Jiandani D, Sauriol L, Aronson R.
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [Abstract] [Full Text] [Related]

  • 3. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R.
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [Abstract] [Full Text] [Related]

  • 4. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P, Jérémie W, Buysschaert M.
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [Abstract] [Full Text] [Related]

  • 5. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG, Min KW, Lim JS, Ahn KJ, Ahn CW, Yu JM, Kim HS, Kim HJ, Kim W, Kim DH, Jang HC.
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [Abstract] [Full Text] [Related]

  • 6. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M, Shaltout I, Malek R, Assaad Khalil S, Ballout H, Annabi F, Shereen M.
    Curr Diabetes Rev; 2024 May; 20(5):e110823219694. PubMed ID: 37581325
    [Abstract] [Full Text] [Related]

  • 7. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE, Malone DC, Trujillo JM, Gill J, Huse S, Li X, Zhou FL, Preblick R, Reid T.
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS, Zhou FL, Gupta RA, Preblick R, Gupta VE, Berhanu P, Blonde L.
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L.
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [Abstract] [Full Text] [Related]

  • 12. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
    Munshi MN, Gill J, Chao J, Nikonova EV, Patel M.
    Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I, Chao J, Dalal MR, Meneghini LF.
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [Abstract] [Full Text] [Related]

  • 14. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J.
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [Abstract] [Full Text] [Related]

  • 15. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH.
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS.
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [Abstract] [Full Text] [Related]

  • 17. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R.
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [Abstract] [Full Text] [Related]

  • 18. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J, White JR.
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [Abstract] [Full Text] [Related]

  • 19. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B, Wiza D, Szczepanik T, Syta A, Klupa T.
    J Diabetes Res; 2020 Oct; 2020():8751348. PubMed ID: 32337298
    [Abstract] [Full Text] [Related]

  • 20. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
    Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS.
    Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.